Immunodeficiency Therapeutics Market to Surpass US$ 10,581.6 Million by 2028

Global Immunodeficiency Therapeutics Market, by Therapy Type (Immunoglobulin Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy, and Others), by Test Type (Blood Test and Prenatal Testing), by Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$  6,991.1 million in 2021, and is expected to exhibit a CAGR of 6.1% during the forecast period (2021-2028).

Rising burden of immunodeficiency disorders such as HIV-AIDS (Human immunodeficiency virus- Acquired immunodeficiency disorder syndrome), ADA-SCID, X-linked SCID, CVID (common variable immune deficiency), and others is expected to drive growth of the global immunodeficiency therapeutics market during the forecast period. For instance, according to the data published by the World Health Organization in 2019, around 400 immunodeficiency ranging from rare to common were recognized which was found to be almost double than the number estimated in 2009.

Initiatives by market players to increase access to immunodeficiency disorder treatments is expected to boost the growth of global immunodeficiency therapeutics market over the forecast period. For instance, in November 2020, AscellaHealth, LLC, a U.S. based pharmacy benefit manager announced the launch of its new Intravenous Immunoglobulin (IVIG) Medication Therapy Management Program to support diagnosis and treatment of immunodeficiency disorders or diseases.

Global Immunodeficiency Therapeutics Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 186 million cases and 4.0 million deaths due to Coronavirus (COVID-19) were reported up till July 11, 2021 across the globe.

The COVID-19 pandemic has affected several markets across the globe however, it is expected to increase the growth of global immunodeficiency therapeutics market owing to increasing need for immunodeficiency therapeutics related to immunodeficiency disorders associated with COVID-19. For instance, according to a study published by Wiley Online Library in May 2021, COVID-19 poses an increased threat to CVID (common variable immune deficiency) patients. The results reveal that around 29% patients suffering from CVID showed moderate to severe COVID-19 infection.

Browse 35 Market Data Tables and 26 Figures spread through 163 Pages and in-depth TOC on Global Immunodeficiency Therapeutics Market, by Therapy Type (Immunoglobulin Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy, and Others), by Test Type (Blood Test and Prenatal Testing), by Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Immunodeficiency Therapeutics Market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/immunodeficiency-therapeutics-market-4543

Moreover, launch of new products is expected to drive the global immunodeficiency therapeutics market growth. For instance, in December 2019, Hetero Drugs, an Indian pharmaceutical company launched its product Taffic which is a three in one antiviral combination drug for the treatment of HIV-AIDS.

Key Takeaways of the Global Immunodeficiency Therapeutics Market:

• The global immunodeficiency therapeutics market is expected to exhibit a CAGR of 6.1% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028) followed by Europe, owing rising number of product launches. For instance, in December 2019, Grifols, S.A., a Spanish pharmaceutical company launched its product called Xembify which is the first 20% liquid formulation of human immunoglobulin to be administered subcutaneously for treatment of primary immunodeficiency diseases.
• Some of the major players operating in the global immunodeficiency therapeutics market include Pfizer Inc., CSL Behring, Grifols, S.A., Abbott, ADMA Biologics, Inc., AstraZeneca, Baxter, Bayer AG, Biocon, Bristol-Myers Squibb Company, BDI Pharma, Inc., Bharat Serums and Vaccines Ltd., Eli Lilly and Company, GlaxoSmithKline plc., Lupin Pharmaceuticals Inc., Novartis AG, Octapharma AG, Sanofi, and Takeda Pharmaceutical Company Limited